Announcements Trials

Browse Landscape

Phase

Phase 2 8 Phase 3 5 Phase NA 2 Phase 1/2 2 Phase 2/3 1 Phase 1 1

Status

Completed 11 Terminated 5 Withdrawn 1 Recruiting 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostate Adenocarcinoma 1

Interventions

pembrolizumab 85 Cyclophosphamide 74 Nivolumab 58 fludarabine 49 Specimen Handling 49 Magnetic Resonance Spectroscopy 43 Carboplatin 41 Biopsy 39 Radiotherapy 32 fludarabine phosphate 30 atezolizumab 27 Gemcitabine 27 Paclitaxel 26 Ipilimumab 26 Cisplatin 24 venetoclax 23 Radiation 23 Dexamethasone 22 Radiosurgery 21 durvalumab 20 Rituximab 20 Temozolomide 18 Lenalidomide 18 Bevacizumab 17 palbociclib 15 Pemetrexed 15 Decitabine 15 Cytarabine 15 130-nm albumin-bound paclitaxel 15 Oxaliplatin 14

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Active not recruiting × bicalutamide × Clear all

NCT04943536 2026-02-27

BiolenRT

Alessa Therapeutics Inc.

Phase 1 Active not recruiting

Prostate Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡